Literature DB >> 12734341

Histone deacetylation, but not hypermethylation, modifies class II transactivator and MHC class II gene expression in squamous cell carcinomas.

Takayuki Kanaseki1, Hideyuki Ikeda, Yukio Takamura, Minoru Toyota, Yoshihiko Hirohashi, Takashi Tokino, Tetsuo Himi, Noriyuki Sato.   

Abstract

In this study, we first categorized nine squamous cell carcinoma (SCC) cell lines into two groups in terms of the expression of HLA-DR, -DP, and -DQ molecules. Subsequently, the expression of class II transactivator (CIITA) was studied in these cell lines, because it is widely accepted that the expression of MHC class II molecules is regulated by different types of CIITA transcripts that are initiated by distinct promoters. The majority of the SCC cell lines (six of nine) expressed HLA-DR molecules and CIITA promoter IV (pIV) transcripts in the presence of IFN-gamma. In contrast, three of the nine SCC cell lines were completely negative for class II molecules and all types of CIITA, suggesting epigenetic changes in the promoter region in these cells. Previously, methylation of CIITA pIV was reported to silence CIITA gene expression. We extensively studied the methylation status of CIITA pIV using a panel of 22 SCC cell lines. Remarkably, none of the SCC cell lines demonstrated hypermethylation at the site. In contrast, treatment with a histone deacetylation inhibitor in combination with IFN-gamma clearly restored the expression of the CIITA type IV gene in the HLA-DR-negative SCC cell lines, and the acetylation status of histone H3 examined by chromatin immunoprecipitation analysis was closely associated with the gene expression. Moreover, stable transfection of the CIITA gene into an HLA-DR-negative cell line restored constitutive expression of MHC class II molecules. Therefore, histone deacetylation, but not hypermethylation, modifies CIITA DNA and class II gene expression in SCC.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12734341     DOI: 10.4049/jimmunol.170.10.4980

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  8 in total

Review 1.  HLA class II antigen-processing pathway in tumors: Molecular defects and clinical relevance.

Authors:  Barbara Seliger; Matthias Kloor; Soldano Ferrone
Journal:  Oncoimmunology       Date:  2017-02-06       Impact factor: 8.110

Review 2.  Histone deacetylase regulation of immune gene expression in tumor cells.

Authors:  A Nazmul H Khan; Thomas B Tomasi
Journal:  Immunol Res       Date:  2008       Impact factor: 2.829

Review 3.  HLA antigen changes in malignant cells: epigenetic mechanisms and biologic significance.

Authors:  M Campoli; S Ferrone
Journal:  Oncogene       Date:  2008-10-06       Impact factor: 9.867

4.  Up-regulation of HLA class-I antigen expression and antigen-specific CTL response in cervical cancer cells by the demethylating agent hydralazine and the histone deacetylase inhibitor valproic acid.

Authors:  María de Lourdes Mora-García; Alfonso Duenas-González; Jorge Hernández-Montes; Erick De la Cruz-Hernández; Enrique Pérez-Cárdenas; Benny Weiss-Steider; Edelmiro Santiago-Osorio; Vianney Francisco Ortíz-Navarrete; Víctor Hugo Rosales; David Cantú; Marcela Lizano-Soberón; Martha Patricia Rojo-Aguilar; Alberto Monroy-García
Journal:  J Transl Med       Date:  2006-12-27       Impact factor: 5.531

Review 5.  Therapeutic Cancer Vaccines-T Cell Responses and Epigenetic Modulation.

Authors:  Apriliana E R Kartikasari; Monica D Prakash; Momodou Cox; Kirsty Wilson; Jennifer C Boer; Jennifer A Cauchi; Magdalena Plebanski
Journal:  Front Immunol       Date:  2019-01-25       Impact factor: 7.561

6.  Expression regulation of major histocompatibility complex class I and class II encoding genes.

Authors:  Peter J van den Elsen
Journal:  Front Immunol       Date:  2011-10-04       Impact factor: 7.561

Review 7.  Exploiting tumor epigenetics to improve oncolytic virotherapy.

Authors:  Nicole E Forbes; Hesham Abdelbary; Mathieu Lupien; John C Bell; Jean-Simon Diallo
Journal:  Front Genet       Date:  2013-09-20       Impact factor: 4.599

8.  Activation of ERα signaling differentially modulates IFN-γ induced HLA-class II expression in breast cancer cells.

Authors:  Ahmed A Mostafa; Dianne Codner; Kensuke Hirasawa; Yumiko Komatsu; Matthew N Young; Viktor Steimle; Sheila Drover
Journal:  PLoS One       Date:  2014-01-27       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.